Litcius/Paper detail

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

Valentín Ortiz‐Maldonado, Susana Rives, María Castellà, Anna Alonso‐Saladrigues, Daniel Benítez‐Ribas, Miguel Caballero‐Baños, Tycho Baumann, Joan Cid, Enric García‐Rey, Cristina Llanos, Montserrat Torrebadell, Neus Villamor, Eva Giné, Marina Díaz‐Beyá, Laia Guardia, Mercedes Montoro, Albert Català, Anna Faura, Esther González, Marta Español‐Rego, Nela Klein-González, Laia Alsina, Pedro Castro, Iolanda Jordán, Sara Fernández, Federico Ramos, Guillermo Suñé, Unai Perpiñá, Josep M. Canals, Miquel Lozano, Esteve Trias, Andrea Scalise, Sara Varea, Joaquín Sáez‐Peñataro, Ferràn Torres, Gonzalo Calvo, Jordi Esteve, Álvaro Urbano-Ispizúa, Manel Juan, Julio Delgado

2020Molecular Therapy157 citationsDOIOpen Access PDF

Topics & Concepts

Refractory (planetary science)MedicineCD19Internal medicineClinical trialMulticenter studyOncologyRandomized controlled trialBiologyPeripheral bloodAstrobiologyCAR-T cell therapy researchVirus-based gene therapy researchNeuroblastoma Research and Treatments
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies | Litcius